Cell Therapy News

Ninety percent of patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic stem cell transplantation had complete response to an investigational chimeric antigen receptor T-cell therapy, according to preliminary data.

John P. Chute, MD, has been appointed director of the division of hematology and cellular therapy in the department of medicine at Cedars-Sinai Cancer.

Janssen and Legend Biotech have begun a rolling submission of a biologics license application to the FDA for ciltacabtagene autoleucel to treat adults with relapsed or refractory multiple myeloma.

The FDA cleared an investigational new drug application for LYG-LIV0001, an allogeneic hepatocyte transplantation solution for end-stage liver disease, according to the agent’s manufacturer.

Molecular and cellular characteristics of commercial chimeric antigen receptor T-cell therapies appeared associated with treatment response and toxicity among patients with large B-cell lymphoma, according to a study in Nature Medicine.

The FDA has approved or granted special designations to several oncology or hematology agents over the past 2 weeks.

This year’s virtual ASH Annual Meeting and Exposition featured hundreds of abstracts that spotlighted research advances in blood cancer and benign hematology research.

The FDA cleared an investigational new drug application for LB1901, a chimeric antigen receptor T-cell therapy in development for treatment of adults with relapsed or refractory T-cell lymphoma, according to the agent’s manufacturer.

Acitretin, apremilast and methotrexate can be used to treat immune checkpoint inhibitors-mediated psoriasis, according to a study published in Journal of the American Academy of Dermatology.

An investigational chimeric antigen receptor T-cell therapy showed antitumor activity among patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to data presented at the virtual ASH Annual Meeting and Exposition.